source
- Abivax shares jump 40% after Phase 3 data show no excess cancer risk for ulcerative colitis drugAbivax reported new safety data from its Phase 3 trial of obefazimod in ulcerative colitis. The data indicated malignancy rates among trial participants were comparable to background rates observed…
- Biotech funding surge: 40 companies secure $100M+ rounds in H1 2026Endpoints News reported that 40 private biotech firms announced funding rounds of at least $100 million each in the first half of 2026. This count surpasses the number recorded for the same period…